UroGen Pharma announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Teva Pharmaceuticals USA, and Teva Pharmaceutical Industries, alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069. Both patents are listed in the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations for JELMYTO for pyelocalyceal solution. JELMYTO is indicated for the treatment of adults with low-grade, upper tract urothelial cancer and utilizes UroGen’s RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology. “UroGen pioneered a significant breakthrough and remains at the forefront of transforming urothelial cancer treatment,” said Liz Barrett, President and CEO, UroGen. “UroGen has full confidence in the strength of its patents and plans to vigorously defend our intellectual property rights.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma price target lowered to $34 from $35 at Oppenheimer
- Urogen Pharma’s UGN-102 Faces Crucial Test: Durability of Response Key to Drug’s Approval Prospects
- URGN Upcoming Earnings Report: What to Expect?
- UroGen Pharma to Present at TD Cowen Health Care Conference
- Teva Challenges UroGen Pharma’s Jelmyto Patent Rights